← Leaderboards
Lori A Styles
University Of California San Francisco
$3,704,916
Attributed
$3,704,916
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $490.3K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$3,704,916 · 7
By mechanism
R01$1,422,870 · 1
U54$769,324 · 1
K24$731,866 · 1
R21$585,000 · 1
R03$152,600 · 1
M01$43,256 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Bertram Harold Lubin$7,666,702
- Elliott P Vichinsky$12,339,152
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaClinical ResearchChild (0-11)Human SubjectHuman Therapy EvaluationStrokeHuman DataPatient Oriented ResearchDisease /Disorder Proneness /RiskPhospholipase A2Drug Screening /EvaluationHeparinSickle Cell CrisisGenetic SusceptibilityPatient Care ManagementBlood TransfusionMedical ComplicationBlood Disorder DiagnosisBlood Disorder ChemotherapyAnticoagulantsPathologic ProcessHuman Genetic Material TagGene Environment InteractionEvaluation
Grant awards (27)
Arginine as Prophylactic Therapy in Sickle Cell Disease$154,621
K24 · FY2009 · HL · contact PI
Arginine as Prophylactic Therapy in Sickle Cell Disease$150,118
K24 · FY2008 · HL · contact PI
Phospholipase A2 Inhibitor Safety Trial$344,536
U54 · FY2007 · HL · contact PI
Arginine as Prophylactic Therapy in Sickle Cell Disease$145,747
K24 · FY2007 · HL · contact PI
PHOSPHOLIPASE A2 INHIBITOR SAFTEY TRIAL$215,082
U54 · FY2006 · HL · contact PI
Arginine as Prophylactic Therapy in Sickle Cell Disease$141,501
K24 · FY2006 · HL · contact PI
PHOSPHOLIPASE A2 INHIBITOR SAFTEY TRIAL$209,706
U54 · FY2005 · HL
Arginine as Prophylactic Therapy in Sickle Cell Disease$139,879
K24 · FY2005 · HL
Chlamydia Infection as a Risk Factor for Cerebrovascula*$360,225
R01 · FY2004 · HL
Chlamydia Infection as a Risk Factor for Cerebrovascula*$360,225
R01 · FY2003 · HL
Chlamydia Infection as a Risk Factor for Cerebrovascula*$360,225
R01 · FY2002 · HL
STROKE RISK IN CHILDREN WITH SICKLE CELL ANEMIA$200,000
R21 · FY2002 · NS
SECRETORY PHOSPHOLIPASE A2 IN ACUTE CHEST SYNDROME TRIAL$0
M01 · FY2002 · RR
EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON SICKLE CELL$0
M01 · FY2002 · RR
Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk$342,195
R01 · FY2001 · HL
STROKE RISK IN CHILDREN WITH SICKLE CELL ANEMIA$200,000
R21 · FY2001 · NS
HLA AS A PREDICTOR FOR STROKE IN SICKLE CELL ANEMIA$76,300
R03 · FY2001 · HL
EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON SICKLE CELL$0
M01 · FY2001 · RR
SECRETORY PHOSPHOLIPASE A2 IN ACUTE CHEST SYNDROME TRIAL$0
M01 · FY2001 · RR
STROKE RISK IN CHILDREN WITH SICKLE CELL ANEMIA$185,000
R21 · FY2000 · NS
HLA AS A PREDICTOR FOR STROKE IN SICKLE CELL ANEMIA$76,300
R03 · FY2000 · HL
SECRETORY PHOSPHOLIPASE A2 IN ACUTE CHEST SYNDROME TRIAL$25,799
M01 · FY2000 · RR
EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON SICKLE CELL$17,457
M01 · FY2000 · RR
SECRETORY PHOSPHOLIPASE A2 IN ACUTE CHEST SYNDROME TRIAL$0
M01 · FY2000 · RR
EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON SICKLE CELL$0
M01 · FY2000 · RR
EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON SICKLE CELL$0
M01 · FY2000 · RR
SECRETORY PHOSPHOLIPASE A2 IN ACUTE CHEST SYNDROME TRIAL$0
M01 · FY2000 · RR